A new once-weekly antiretroviral pill for HIV treatment has shown promising interim results in South Africa, according to studies presented at the AIDS 2026 conference.

The pill, containing islatravir and lenacapavir, was found to be as effective as daily regimens in suppressing viral loads, with zero participants in one study experiencing viral load above the 50 copies/mL threshold.

Researchers from the ISLEND-1 and ISLEND-2 trials, involving over 1,200 patients, noted that the weekly pill is well-tolerated and could simplify treatment adherence.Professor Francois Venter highlighted its potential to reduce pill fatigue and logistical challenges, while Dr.Amy Colson explained that reporting bias might explain higher adverse event reports in open-label studies.The findings, though preliminary, suggest the pill could become a game-changer in HIV management, especially in low-resource settings.Gilead Sciences and Merck are planning global regulatory filings, but pricing and accessibility remain concerns.

The study underscores the need for innovative treatments to combat HIV, with the weekly pill offering a simpler dosing schedule that may improve patient compliance and reduce healthcare burdens.